Given the importance of pre-existing anti-tumor immunity in the setting of checkpoint blockade 31, models adjusting for PD-L1 reactive expression might have important clinical implications for anti-PD-1/PD-L1 therapies. The gene discussed is CD274; the disease is neoplasm.